Most recently, the FIDELIO-DKD trial reported that MR antagonism, with finerenone, lowered the risk of CKD progression, reduced albuminuria, and reduced cardiovascular events in patients with CKD and type 2 diabetes, further highlighting the utility of MR antagonists in clinical practice (13). The gene discussed is NR3C2; the disease is type 2 diabetes mellitus.